Why in hospital following transoral robotic lingual tonsillectomy?
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Background
The reported hospital length of stay (LOS) following transoral robotic surgery lingual tonsillectomy (TORS-L) is variable, with limited understanding of the factors requiring hospitalization and no evidence-based criteria for discharge.
Aims/objectives
This observational cohort study investigated factors hindering discharge following TORS-L in a well-defined postoperative care program.
Methods
Patients were included between August 2020 and October 2022. A discharge scheme was filled out twice daily, specifying the factor(s) for hospitalization among patients undergoing TORS-L. This trial was a sub-investigation of a national multicentre randomized clinical trial (RCT) testing the efficiency of high-dose dexamethasone on postoperative pain control. Participation in the RCT demanded admission to the fourth postoperative day as dexamethasone/placebo was given intravenously in repeated dosages till day 4 postoperatively.
Results
Eighteen patients were included in the analysis. The main factor for hospitalization was nutritional difficulties, while pain was a limiting factor for discharge only on the first postoperative 1-3 days. More than half of the patients could have potentially been discharged on postoperative day 2 when omitting the RCT treatment plan in the analysis.
Conclusion
The study estimates that the majority of patients may be discharged on postoperative day 2 following TORS-L.
The reported hospital length of stay (LOS) following transoral robotic surgery lingual tonsillectomy (TORS-L) is variable, with limited understanding of the factors requiring hospitalization and no evidence-based criteria for discharge.
Aims/objectives
This observational cohort study investigated factors hindering discharge following TORS-L in a well-defined postoperative care program.
Methods
Patients were included between August 2020 and October 2022. A discharge scheme was filled out twice daily, specifying the factor(s) for hospitalization among patients undergoing TORS-L. This trial was a sub-investigation of a national multicentre randomized clinical trial (RCT) testing the efficiency of high-dose dexamethasone on postoperative pain control. Participation in the RCT demanded admission to the fourth postoperative day as dexamethasone/placebo was given intravenously in repeated dosages till day 4 postoperatively.
Results
Eighteen patients were included in the analysis. The main factor for hospitalization was nutritional difficulties, while pain was a limiting factor for discharge only on the first postoperative 1-3 days. More than half of the patients could have potentially been discharged on postoperative day 2 when omitting the RCT treatment plan in the analysis.
Conclusion
The study estimates that the majority of patients may be discharged on postoperative day 2 following TORS-L.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Acta Oto-Laryngologica |
Vol/bind | 143 |
Udgave nummer | 9 |
Sider (fra-til) | 796-800 |
Antal sider | 5 |
ISSN | 0001-6489 |
DOI | |
Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:
This study was supported by a private non-profit foundation, Candys Foundation (Grant ID: 2019-304), Forskningspuljen mellem OUH og RH (Grand ID: A4723) and Region Hovedstadens Forskningsfond til Sundhedsforskning (Grant ID: A6682)
Publisher Copyright:
© 2023 Acta Oto-Laryngologica AB (Ltd).
ID: 395913337